Search results
Results from the WOW.Com Content Network
Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. [10] It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). [10] It is taken by mouth. [10]
The factors with the greatest risk associations are hyperlipidemia, hypertension, diabetes mellitus, chronic kidney disease, and smoking. Presenting three of these factors or more increases the risk of developing PAD tenfold. [38] Smoking – Tobacco use in any form is the single greatest risk factor for peripheral artery disease internationally.
Both aspirin and clopidogrel may be useful in the first few weeks after a minor stroke or high-risk TIA. [128] Clopidogrel has less side effects than ticlopidine. [127] Dipyridamole can be added to aspirin therapy to provide a small additional benefit, even though headache is a common side effect. [129]
For many years dual treatment with the cyclooxygenase-1 (COX-1) inhibitor aspirin and clopidogrel was routine practice and served as the main antiplatelet agents for the prevention of thrombotic events as they have the capability to powerfully manipulate platelet biology, which plays a central part in thrombosis.
Often a combination of aspirin plus an ADP/P2Y inhibitor [7] (such as clopidogrel, prasugrel, ticagrelor, or another) is used to obtain greater effectiveness than with either agent alone. This is known as "dual antiplatelet therapy" (or DAPT ).
A high score corresponds to a greater risk of stroke, while a low score corresponds to a lower risk of stroke. The CHADS 2 score is simple and has been validated by many studies. [ 2 ] In clinical use, the CHADS 2 score (pronounced "chads two") has been superseded by the CHA 2 DS 2 -VASc score ("chads vasc" [ 3 ] ), which gives a better ...
In the US, ticagrelor is indicated to reduce the risk of stroke in people with acute ischemic stroke or high-risk transient ischemic attack. [5]In the EU, ticagrelor, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events in adults with acute coronary syndromes or a history of myocardial infarction and a high risk of developing an ...
After TIA or minor stroke, aspirin therapy has been shown to reduce the short-term risk of recurrent stroke by 60–70%, and the long-term risk of stroke by 13%. [24] The typical therapy may include aspirin alone, a combination of aspirin plus extended-release dipyridamole, or clopidogrel alone. [21]